Molecular Partners AG reported a net loss of CHF 26.7 million for the first half of 2026, a significant improvement from the CHF 37.2 million loss recorded in H1 2025. The Zurich-based clinical-stage biotech company also disclosed a cash position of CHF 67.9 million as of June 30, 2026.

The company attributed the narrower loss to disciplined cost management and progress in its clinical pipeline, particularly its lead Radio-DARPin candidate MP0712. Management stated that current cash reserves are sufficient to fund operations into late 2027, excluding potential payments from research and development partnerships.

Financial Performance

Total operating expenses fell by CHF 6.5 million year-over-year to CHF 27.0 million in H1 2026, compared to CHF 33.5 million in the same period last year. This reduction was driven primarily by lower restructuring expenses, which were nil in the current period versus CHF 2.7 million in H1 2025.

Research and development expenses decreased by CHF 3.6 million to CHF 19.0 million, while selling, general, and administrative expenses remained relatively stable at CHF 8.0 million, down slightly from CHF 8.2 million. Net cash used in operating activities improved by CHF 5.2 million to CHF 25.0 million, reflecting the lower burn rate.

What the Numbers Show

The divergence between the net loss and operating cash outflow highlights the impact of non-cash charges on the company's bottom line. While the net loss narrowed by CHF 10.5 million, operating cash usage declined by only CHF 5.2 million. This gap suggests that non-cash items, such as share-based payments and depreciation (estimated at approximately CHF 6 million annually), constitute a material portion of the reported expense reduction, preserving more cash than the income statement alone might indicate.

Additionally, the company reduced its full-time employee headcount by 36.3, from 153.0 FTEs in H1 2025 to 116.7 FTEs in H1 2026. This workforce contraction aligns with the reduction in restructuring expenses and supports the broader trend of operational efficiency amidst zero revenue generation.

Pipeline Progress

Molecular Partners advanced its lead program, MP0712, a DLL3-targeting Radio-DARPin therapy for small cell lung cancer. The Phase 1/2a study has progressed to dose level 2 after cohort 1 completed safety observations with no dose-limiting events. Initial clinical data is expected later in 2026, with comprehensive efficacy data anticipated in 2027.

The company also selected CD70 as its third target for its radio-therapeutic pipeline, focusing on kidney cancer and other indications. IND-enabling work for this program is slated to begin in the second half of 2026, with clinical entry expected in 2027.

Molecular Partners AG announced the dosing of first patients in a randomized Phase 2 proof-of-concept study of MP0317 in combination with chemoimmunotherapy for first-line treatment of advanced biliary tract carcinoma (TACTIC), also known as cholangiocarcinoma. The multicenter study in France aims to recruit 75 patients with a 2-to-1 design, assessing the clinical benefit of MP0317 combined with standard-of-care (SoC) durvalumab and gemcitabine-cisplatin-based chemotherapy compared to SoC alone. Nine expert trial sites are activated, and patient treatment is ongoing. A data update is expected in 2027, with study completion in 2028. A trial-in-progress poster will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

MP0317 Mechanism and Phase 1 Results

MP0317 is a FAP-localized CD40 agonist designed to drive immune-mediated remodeling of the tumor microenvironment (TME). The company hypothesizes that MP0317 will improve the 12-month progression-free survival rate compared to SoC alone. Molecular Partners completed a Phase 1 dose-escalation study treating 46 patients across 9 dose levels. Comprehensive biomarker analyses showed tumor-localized CD40 activation and TME remodeling as intended. These results were recently published in Nature Cancer.

Clinical Progress and Management Commentary

"Adding an immune modulating compound with the profile of MP0317 to front-line therapy could offer deeper and longer responses for cholangiocarcinoma patients who are receiving SoC," said Prof. Christophe Borg, Head of the Medical Oncology Department at the University Hospital of Besançon and Principal Investigator of the TACTIC study. "To date we have treated a number of patients through several cycles, and the study is advancing according to plan."

"We are proud to support the TACTIC consortium in pursuing this novel treatment for patients with such a dire need for improved therapies," said Philippe Legenne, M.D., CMO of Molecular Partners. "MP0317 has shown proof-of-mechanism in the completed Phase 1 study... We believe MP0317 could potentiate the effect of SoC for greater patient benefit across several cancer indications."